Cargando…
Sitagliptin may reduce prostate cancer risk in male patients with type 2 diabetes
This retrospective cohort study evaluated the risk of prostate cancer associated with sitagliptin use in Taiwanese male patients with type 2 diabetes mellitus by using the reimbursement databases of the National Health Insurance. Male patients with newly diagnosed type 2 diabetes mellitus at an age...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Impact Journals LLC
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5386669/ https://www.ncbi.nlm.nih.gov/pubmed/27661113 http://dx.doi.org/10.18632/oncotarget.12137 |